



This is a repository copy of *Role of remote ischaemic conditioning in fracture healing and orthopaedic surgery—a systematic review and narrative synthesis*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/226535/>

Version: Published Version

Article:

Buck, A., Wang, T., Baig, S.S. et al. (2 more authors) (2025) Role of remote ischaemic conditioning in fracture healing and orthopaedic surgery—a systematic review and narrative synthesis. *Journal of Orthopaedic Surgery and Research*, 20 (1). 448. ISSN 1749-799X

<https://doi.org/10.1186/s13018-025-05772-6>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

SYSTEMATIC REVIEW

Open Access



Role of remote ischaemic conditioning in fracture healing and orthopaedic surgery—a systematic review and narrative synthesis

Alison Buck¹, Tao Wang², Sheharyar S. Baig², Arshad Majid² and Ali N. Ali^{3*}

Abstract

Introduction Remote ischaemic conditioning (RIC) involves the use of controlled and transient ischemia and reperfusion cycles, commonly of the upper or lower limb, to mitigate cellular damage from ischaemic events. Studies have demonstrated that RIC may have anti-inflammatory and cardiovascular protective effects and thus could represent a novel therapeutic strategy to improve outcomes following orthopaedic surgery. This review aimed to comprehensively describe the current pre-clinical and clinical evidence for RIC in orthopaedics.

Methods MEDLINE and EMBASE via OVID (1966—March 2024) were searched using a systematic search strategy for randomised controlled trials (RCTs) investigating the effects of RIC on fracture, bone healing, and orthopaedics. Both pre-clinical and clinical RCTs were included.

Results Three pre-clinical RCTs (comprising of 198 rats in models of experimental fracture) met the inclusion criteria. These showed that RIC was associated with enhanced callus formation (volume and biomechanical strength) post-fracture, reduced oxidative stress and upregulated osteoblastic activity. Sixteen clinical RCTs, involving 628 patients, investigated RIC in 6 different elective orthopaedic procedures (knee, lower limb, cervical, shoulder, general, hip fracture). RIC protocols varied in cycle frequency, duration, and pressure, but all were given as a single dose at induction of anaesthesia. Significant results included reductions in oxidative stress, improved cerebral and peripheral oxygenation, and reduced pain scores and analgesia use. Only 1 study (n = 648) evaluated RIC in acute hip fracture and demonstrated an early cardioprotective effect.

Conclusion The potential therapeutic effects of RIC in orthopaedic surgery is supported by preliminary evidence from pre-clinical and clinical studies. Trials to date are largely small but warrant investigation in well-powered multi-centre RCTs. There are still many unanswered questions about the optimal RIC parameters (cuff pressure, frequency and duration) in orthopaedic surgery and determining which patients may benefit most from this therapy.

Keywords Remote ischaemic conditioning, Ischaemia, Stroke, Myocardial infarction, Elective surgery, Emergency surgery

*Correspondence:

Ali N. Ali

ali.ali@sheffield.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Background

Orthopaedic surgery is a common treatment option for acute and chronic musculoskeletal disorders [1]. Rates of bone fractures are rising [2] particularly in the elderly, and along with arthritis and pain syndromes contribute to adult-onset disability [2]. Consequently a third of the population suffer pain, stiffness and restricted movement impacting negatively on quality of life [3]. In the UK's National Health Service (NHS), 25% of all surgical interventions are for musculoskeletal conditions with orthopaedic procedures accounting for 16.1% of the total cost of surgery [4]. An ageing and multimorbid population increase the risk of post-surgical complications including myocardial infarction, stroke, delayed healing, and infection [5]. Hip fractures in particular require hospitalisation and surgical repair [6] and affect 70,000 individuals in the UK annually, costing an estimated £1.1 billion [7]

and is expected to double by 2040 [8, 9]. Mortality after hip fracture remains high at 6.1% in the first month, rising to 33% at one year in the UK. Thus, there is an unmet need for interventions that mitigate the risk of such post-surgical complications [9].

Remote ischaemic conditioning (RIC) is a technique which induces intermittent ischaemia of the upper or lower limb, through inflating a pressure cuff above systolic blood pressure for intervals that avoid physical injury, but trigger a number of intrinsic protective mechanisms [10] (Fig. 1a). RIC was first shown to reduce infarct size in animal models of myocardial infarction in the 2000 s [11]. Since then, RIC has been studied in ischaemia–reperfusion injury of other organs such as the brain, kidney and liver, as well as for conditions such as sepsis and renal failure [12, 15]. Depending on timing of RIC relative to ischaemia, RIC is referred to as remote




Fig. 1 **a** Postulated mechanisms of action of remote ischaemic conditioning (RIC). **b** Different paradigms of remote ischaemic conditioning (RIC) delivery

ischaemic preconditioning (RIPreC), preconditioning (RIPerC) or post-conditioning (RIPostC) [12] (Fig. 1b).

The underlying mechanism of action of RIC is thought to be mediated via humoral (release of blood-based signalling molecules such as nitric oxide), neuronal (activation of peripheral and central autonomic fibres) and immunoregulatory (suppression of pro-inflammatory cytokine production) pathways [16, 19]. The downstream effects of these, included improved mitochondrial and endothelial function may increase resilience to future bouts of ischaemia, both locally and systemically. [20, 21]. Furthermore, RIC has also been postulated to have effects on bone repair mechanisms and pain modulation in preclinical models and in clinical studies [22, 23] of fracture and musculoskeletal injury. As such, RIC may be a promising, low-cost adjuvant therapy in elective and emergency orthopaedic interventions.

This systematic review represents a comprehensive and contemporaneous review of the preclinical and clinical evidence to date that investigates its use in fracture healing and orthopaedic surgery.

Methods

This systematic review followed the PRISMA reporting guidelines [24] (Additional file 1).

Inclusion and exclusion criteria

Studies were included if they evaluated the effects of RIC on fracture healing, trauma, hip fracture or orthopaedic surgery. Only randomised controlled trials (RCTs) were included, both preclinical and clinical. We included all studies independent of the protocol of RIC used or their primary and secondary outcomes. Only articles written in English were included.

Search strategy

The following electronic databases were searched from 1966 to March 2024: MEDLINE via OVID and EMBASE via OVID. Subject heading and free text terms relating to RIC (e.g. ischaemic conditioning, remote ischaemic conditioning, preconditioning, preconditioning, postconditioning), fracture (e.g. trauma, bone injury, fracture, hip fracture, break, fragility, bone healing), and orthopaedics (e.g. musculoskeletal, orthopaedics, trauma, ligament, meniscus, elective, emergency, operative, tissue, muscle, cartilage) were used to produce a search strategy for OVID MEDLINE (Additional file 2). This was adjusted using Boolean operators for EMBASE. Reference lists of included studies and reviews were scanned for relevant additional articles.

Study selection and data extraction

The initial search results were reviewed independently by 2 authors (AB and AA), duplicate and irrelevant articles were removed from screening titles and abstracts. Full texts of the remaining articles were then reviewed for final inclusion, and data extracted into a pre-designed spreadsheet. This included author details, study design, population or animal models, intervention details (timing of RIC, pressure protocols used, limbs conditioned), outcome measures reported, and clinical findings. Disagreements on study inclusion or outcomes were adjudicated by a third reviewer (TW).

Study quality assessment

Two reviewers (AB and AA) independently reviewed each study. Preclinical studies were assessed using the SYRCLE's tool for assessing risk of bias [25] composed of 10 items including: allocation sequence generation; similarity of baseline characteristics; allocation concealment; housing of animals; investigator blinding; random outcome assessment; blinding of assessments; completeness of data collection; selectivity or reporting and other sources of bias. Reporting of items in study manuscripts or protocols accrue a point each, with a maximum score of 10. Clinical studies were reviewed using the PEDro scale [26], a 10-item checklist addressing similar concepts based on the following: specification of eligibility criteria; randomisation; concealment of allocation; similarity of group baseline characteristics, subject blinding; blinding of therapists and assessors; completeness of data collection; proportion of allocated individuals receiving intended treatments or inclusion of 'intention to treat' analyses; between group statistical comparisons; and provision of measures of variability in outcome measures. Item 1 (eligibility criteria) of the PEDro is not scored, but presence of other quality markers accrue a point each so that a total of 10 is achieved for the highest quality studies. Scores of 0–3 are considered 'poor'; 4–5 'fair'; 6–8 'good' and 9–10 'excellent'.

Data analysis and narrative review

Study characteristics and outcomes were qualitatively synthesised and summarised in tabular form. Due to the heterogeneity of study populations, RIC protocols and outcomes assessed we were unable to perform meta-analyses of outcome measures. We thus undertook a narrative synthesis of the available evidence using the framework published by the Cochrane Consumers and Communication Review Group [27].

Results

Study selection

Initial searches identified 2,169 studies, of which 2032 remained after duplicates were removed. After screening title and abstracts 39 full text articles were identified for full review, of which 23 articles were finally included in the analysis. This composed of 3 preclinical (3 articles) and 16 clinical RCTs (20 articles, 4 of which reflected the same hip fracture clinical RCT with

differing outcomes) as shown in the study flow diagram (Fig. 2).

Quality assessment

Assessment of study methodological quality revealed very poor reporting of methods for randomisation, concealment of allocation, blinding and randomly selecting animals in preclinical studies (Table 1). In clinical studies, reporting of methods of allocation concealment was low




Fig. 2 Study flow diagram

Table 1 SYRCLEs risk of bias assessment for preclinical RCTs

Authors	Random allocation	Baseline characteristics	Allocation concealment	Animal housing	Caregiver blinding	Random animal selection	Blinded assessments	Completeness of data	Selective reporting	Other biases	Total Score
Catma et al. (2015) [28]	No	No	No	Yes	No	No	Yes	Yes	Yes	No	4
Zhou et al. (2017) [29]	No	No	No	Yes	No	No	No	Yes	Yes	No	3
Qiao et al. (2019) [30]	Yes	No	No	Yes	No	Yes	No	yes	Yes	No	5

(65% of studies) as was methods of blinding, particularly to those completing surgery (30%) and undertaking outcome assessments (65%) (Table 2).

Pre-clinical evidence

Three placebo-controlled studies evaluated RIC in rat models of fracture [29, 30, 30]. In total, 198 rats were used in protocols including RPreC (n = 1) [28] and RPostC (n = 2) [29, 30] interventions. One study also comparing RPostC to intermittent hypoxia training (IHT) and a control group [30]. RPreC was performed with seven cycles of five minutes intermittent pneumatic tourniquet to the hind limb prior to fracture (timing pre-fracture not specified) [28]. RPostC protocols included daily hind limb occlusion by tourniquet for three cycles of 10 min for 7 or 28 days [29, 30]. Intervention characteristics and outcome measures are summarised in Table 3.

Outcome measures of bone healing such as callus volume and maturity were shown to be increased with RIC compared to controls in all three studies. Biomechanical assessment in both RPostC studies also showed that RIC groups had stronger fracture healing than controls, although it was also greater in the IHT group [29, 30]. Serum malondialdehyde (MDA) levels, a marker of oxidative stress, were statistically lowered following RPreC [28]. Osteoblast expression markers including vascular endothelial growth factor (VEGF), Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteocalcin were upregulated, as well as the target gene Hypoxia-inducible factor-1alpha (HIF-1 α), in the RPostC studies compared to control (with the IHT also showing higher expression) [29, 30]. These findings suggest that the potential mechanisms of action on improved fracture healing, may be mediated via a reduction in oxidative stress and an enhanced osteoblastic response.

Clinical evidence in elective orthopaedic surgery

Remote ischaemic conditioning has been investigated in elective orthopaedic surgery and 16 randomised controlled trials (RCTs) were reviewed (see Table 4) [32–46, 46]. Two manuscripts used the same participants and so were considered a single study [33, 34].

In total, there were 628 participants, study sizes ranged from 20 to 72 participants. Thirteen studies included blinding methods, seven of these were double or triple blinded. Overall 12 of the 15 RCTs were rated good or excellent on PEDro quality rating [32, 36–38, 38, 41–50, 50]. The studies recruited participants undergoing total knee arthroplasty (n = 7) [32–38, 38], other populations of lower limb surgery (n = 5) [41–43, 43], cervical spondylosis decompression (n = 1) [44], shoulder surgery (n = 1) [45] and patients with a history of ischaemic heart disease undergoing orthopaedic

surgery (n = 1) [46]. RPreC in this context was considered safe with no studies reporting severe adverse events related to the intervention.

All RCTs used remote ischaemic preconditioning (RPreC), described as being immediately prior to surgery, either before or after anaesthetic induction. RPreC protocols included one (n = 3) [31, 35, 41] or three (n = 12) [33, 34, 34, 37–40, 40, 43–46, 46] cycles of five minutes of ischaemic conditioning. Pressures protocols varied and included double systolic blood pressure (SBP) (n = 2) [32, 45], 100 mmHg above SBP (n = 4) [33, 36, 37, 39], 50 mmHg above SBP (n = 1) [38] or ranged from 200 to 480 mmHg numerically (n = 7) [31, 32, 34, 35, 41–46, 46]. In lower limb surgery, nine out of the eleven studies which recorded the limb RIC was applied to, applied the cuff to the operated limb prior to tourniquet for surgery. RPreC is herein referred to simply as RIC. A primary outcome was documented in 12 studies [32–36, 36, 38, 41, 42, 42, 45, 46, 46] and can be seen in Table 4.

Markers of oxidative stress were measured in six trials [33, 34, 37, 41, 43, 44] and were shown to be statistically significantly reduced in five [32, 33, 36, 40, 42] of these when comparing RIC to control. One study used micro-array from muscle biopsy of the operative leg to demonstrate a differential expression of 257 genes at the start of surgery and 786 genes one hour in to surgery. Some of the genes which were up-regulated were COX18, COX11, UCP3, TIMM10, MRPL43 and PDK4. Gene ontology analysis showed an increase in the expression of important oxidative stress defence genes, immediate early response genes and mitochondrial genes. There was also upregulation of pro-survival genes and a downregulation of pro-apoptotic genes in RIC treated participants [33].

Immune markers were measured by seven studies [32, 33, 33, 35, 39, 42, 45], however outcomes were varied with only three showing statistically significant changes [33, 39, 42]. Two of 6 studies measuring the inflammatory cytokine interleukine-6 (IL-6) demonstrated significant reductions with RIC [33, 42], while one of 2 studies measuring interleukin-8 (IL-8) demonstrated reductions [42]. Another study demonstrated a reduction in activation of CD4 cells, proinflammatory cytokine production IL-2, prevention of CD4/CD8 derangement and lymphocyte directed immune dysfunction [39].

Markers of neurone damage, dysfunction or recovery were measured by two studies [34, 44], both of which demonstrated statistically significant results. One study used micro-array to demonstrate downregulation of genes involved in neuronal apoptosis [34], the other showed increased neurologic recovery rate and a reduction in serum S-100B and neuron-specific enolase, early markers of neurologic dysfunction [44].

Table 2 PEDro score for methodological quality of included clinical RCTs

Authors	Eligibility criteria	Random allocation	Allocation concealment	Baseline characteristics	Subject blinding	Interventionist blinding	Blinded assessments	Completeness of data	Intention to treat	Statistical comparisons	Measures of variability	Total Score
Memtsoudis et al. (2010) [31]	No	Yes	No	Yes	No	No	No	Yes	Yes	Yes	Yes	5
Oh et al. (2017) [32]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Murphy et al. (2010) [33]	Yes	Yes	Yes	No	Yes	No	No	No	No	Yes	Yes	5
Sha et al. (2014) [34]	Yes	Yes	Yes	No	Yes	No	No	No	No	Yes	Yes	5
Memtsoudis et al. (2014) [35]	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	8
Leurcharumee et al. 2022a [36]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Leurcharumee et al. 2022b [37]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Arikan et al. (2023) [38]	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	Yes	7
Sullivan et al. (2009) [39]	Yes	Yes	No	Yes	No	No	No	No	No	Yes	Yes	4
Koca et al. (2011) [40]	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	9
Orban et al. (2006) [41]	Yes	Yes	No	Yes	Yes	No	No	No	Yes	Yes	Yes	6
Lin et al. (2010) [42]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	8
Van et al. (2008) [43]	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	7
Hu et al. (2010) [44]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Oh et al. (2020) [45]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Park et al. (2018) [46]	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9
Ekeloef et al. (2019) [47]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	8
Ekeloef et al. (2021a) [48]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	8
Ekeloef et al. (2021b) [49]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	8

Table 2 (continued)

Authors	Eligibility criteria	Random allocation	Allocation concealment	Baseline characteristics	Subject blinding	Interventionist blinding	Blinded assessments	Completeness of data	Intention to treat	Statistical comparisons	Measures of variability	Total Score
Wahlstrøm et al. (2021) [50]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	8
Total %	95%	100%	65%	85%	60%	30%	65%	80%	85%	100%	100%	

Table 3 Preclinical studies of RIC in bone healing following tibial fracture

Study	Population	%Male	Intervention	Numbers (control, intervention)	Type of RIC	Location	Measurements	Statistically significant results associated with RIC
Catma et al. (2015) [28]	Wistar-Hannover Rats	50	7 cycles of 5 min	48 (24, 24)	Pre (Timing not specified)	Hind limb (Ipsilateral)	Radiographs, histological evaluation, serum MDA levels	Increased callus maturity on histological analysis Lower MDA levels at the first week but not at the third and fifth week
Zhou et al. (2017) [29]	Sprague–Dawley Rats	100	3 cycles of 10 min daily for 7 days	64 (32, 32)	Post	Hind limb (Contralateral)	Radiographs, fracture zone for RT-qPCR, western blotting, immunohistochemistry, micro-CT and biomechanical testing	Increase in callus volume at day 14 and 28 on micro-CT Increased protein and mRNA expression of HIF-1 α Up-regulation of downstream genes VEGF, Runx2, ALP and OCN protein Stronger fracture healing on biomechanical assessment
Qiao et al. (2019) [30]	Sprague–Dawley Rats	100	3 cycles of 10 min daily for 28 days Intermittent hypoxia training 5 min of 5 cycles post surgery	96 (32, 32, 32 IHT)	Post	Hind limb (Contralateral)	Radiographs, RT-qPCR analysis, western blotting, micro-CT and biomechanical testing	Increased markers of bone healing in IHT and RIPostC on micro-CT and radiographs Up-regulation of osteoblast expression markers VEGF, Runx2, ALP and OCN, as well as target gene HIF-1 α , in the IHT and RIPostC

IHT = intermittent hypoxia training; MDA = malondialdehyde; RT-qPCR = reverse transcription-quantitative polymerase chain reaction; micro-CT = micro-computed tomography; VEGF = vascular endothelial growth factor; Runx2 = Runt-related transcription factor 2; ALP = alkaline phosphatase; OCN = osteocalcin; HIF-1 α = Hypoxia-inducible factor-1 alpha

Table 4 Summary characteristics of RCTs of RIC in elective orthopaedic procedures

Authors	Type of study	Population	Intervention	Numbers (control, intervention)	Pressure	Location	Primary outcome	All reported outcome measures	Statistically significant results compared to placebo
Memtsoudis et al. (2010) [31]	Randomised, controlled	Total knee arthroplasty	1 cycle of 5 min	34 (17, 17)	250 mmHg	Operated limb	IL-6	Serum IL-6, CRP, TNF-alpha, leucocyte count. Urine desmosine levels Pain score, length of stay (LOS)	Improved pain score, reduced LOS
Oh et al. (2017) [32]	Randomised, controlled, double-blinded	Total knee arthroplasty	3 cycles of 5 min	72 (36, 36)	Double systolic blood pressure	Opposite thigh to operated limb	Regional cerebral oxygenation saturation (rScO ₂)	rScO ₂ , ratio of the arterial oxygen partial pressure to the fractional inspired oxygen (PF ratio) HR, MAP Hct, lactate, Transfusion requirements, bleeding levels Serum CPK, LDH, AST, creatinine, IL-6, TNF-alpha, IL-10, TGF-beta Postoperative cognitive dysfunction (POCD) using confusion assessment method (CAM)	Higher HR, improved rScO ₂ , improved PF ratio, reduced LDH, reduced transfusion requirements and bleeding levels

Table 4 (continued)

Authors	Type of study	Population	Intervention	Numbers (control, intervention)	Pressure	Location	Primary outcome	All reported outcome measures	Statistically significant results compared to placebo
Murphy et al. (2010) [33]	Randomised, controlled, single-blinded	Total knee arthroplasty	3 cycles of 5 min	20 (10, 10)	100 mmHg above systolic blood pressure	Operated limb	Genomic response in muscle biopsies taken from the operative leg using microarray	Muscle biopsy and serum for gene expression profiles (micro-array and real time PCR) Hb, CRP, ESR, WCC IL-8, TNF-alpha, INF-gamma, IL-1-beta, IL-2, IL-10, IL-12, GM-CSF	Increase in expression of oxidative stress defence genes, immediate early response genes and mitochondrial genes. Upregulation of pro-survival genes was also observed and correlated with a downregulation of pro-apoptotic gene expression. Reduction in IL-6
Sha et al. (2014) [34]								Microarray expression profile from muscle biopsy	Down regulation of genes involved in neurological regulation of neuron apoptosis
Memtsoudis et al. (2014) [35]	Randomised, controlled, double-blinded	Total knee arthroplasty	1 cycle of 5 min	60 (30, 30)	250 mmHg	Operated limb	Postoperative pain using visual analogue scale (VAS)	VAS score, analgesic consumption Intraarticular fluid for TNF-alpha, IL-6 Periarticular circumference Muscle tissue oxygenation (by infrared spectroscopy) Prothrombin fragments F1/F2, d-dimer, Thrombin-antithrombin complex (TAT)	Reduced pain score at rest and with exercise
Leurcharusmee et al. 2022a [36]	Randomised, controlled, triple-blinded	Total knee arthroplasty	3 cycles of 5 min, CoQ10 28 days perioperatively	44 (10 control, 12 CoQ10, 14 RiPreC, 8 CoQ10 & RiPreC)	100 mmHg above systolic blood pressure	Operated limb	Mitochondrial oxygen consumption rates (OCRs) of peripheral blood mononuclear cells (PBMC) as a marker of oxidative phosphorylation	Venous blood PBMCs, postoperative pain scores using numeric rating scale (NRS) and morphine consumption	Increase in basal and ATP-linked respiration at two hours after reperfusion. (Morphine consumption was lower in CoQ10 group.)

Table 4 (continued)

Authors	Type of study	Population	Intervention	Numbers (control, intervention)	Pressure	Location	Primary outcome	All reported outcome measures	Statistically significant results compared to placebo
Leurcharusmee et al. 2022b [37]	Randomised, controlled, double-blinded	Total knee arthroplasty	3 cycles of 5 min	24 (10, 14)	100 mmHg above systolic blood pressure	Operated limb	NR	Western blot analysis of muscle protein. Muscle strength. Health-related quality of life using the Thai version of EQ-5D	Increased mitofusin-2 protein and Opa1 protein expression. Preserved postoperative quadriceps muscle strength
Arıkan et al. (2023) [38]	Randomised, controlled, double-blinded	Total knee arthroplasty	3 cycles of 5 min	60 (30, 30)	50 mmHg above systolic blood pressure	Upper arm	Total thiol-disulfide levels	Serum thiol-disulfide levels for thiol-disulfide homeostasis. Post-operative pain using VAS, nausea and vomiting (4 point scale)	Lower pain score at 15 th hour postop
Sullivan et al. (2009) [39]	Randomised, controlled, partial investigator-blinded	Cruciate ligament surgery	3 cycles of 5 min	25 (13, 12)	100 mmHg above systolic blood pressure (but not less than 250 mmHg)	Operated limb	NR	IL-2, IL-4, IL-6, IFN γ . T cell surface expression of CD45, CD62L and CD95. T cell CD4/CD8 and Th1/Th2 shifts	Reduced activation and proinflammatory cytokine production by CD4 cells, prevented CD4/CD8 derangement and lymphocyte directed immune dysfunction. Reduced serum IL-2
Koca et al. (2011) [40]	Randomised, controlled	Arthroscopic knee surgery	3 cycles of 5 min, 10 mg/kg intravenous N-acetylcysteine (NAC)	45 (15, 15, 15 NAC)	NR	NR	Serum malondialdehyde (MDA)	MDA, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), total antioxidant capacity (TAC), and total oxidant status (TOS)	Reduced mean serum MDA, TOS, SOD and GSH-Px levels
Orban et al. (2006) [41]	Randomised, controlled, single-blinded	Knee ligamentoplasty	1 cycle of 5 min, 1200 mg oral acetylcysteine	31 (11, 10, 10 acetylcysteine)	350 mmHg	Operated limb	Venous blood creatinine phosphokinase (CPK)	Myoglobin, CPK, potassium, phosphorus, lactate. Muscular strength of quadriceps of operated limb (by ASIA motor score). Morphine consumption, VAS	Lower morphine consumption in acetylcysteine and RPreC groups

Table 4 (continued)

Authors	Type of study	Population	Intervention	Numbers (control, intervention)	Pressure	Location	Primary outcome	All reported outcome measures	Statistically significant results compared to placebo
Lin et al. (2010) [42]	Randomised, controlled, double-blinded	Unilateral lower limb surgery	3 cycles of 5 min	30 (15, 15)	480 mmHg	Operated limb	Arterial-alveolar oxygen tension (a/A) ratio	Arterial blood gas, a/A ratio, alveolar-arterial oxygen tension difference (A-aDO ₂), respiratory index Plasma MDA, serum IL-6, IL-8, IL-10	Reduced change in arterial pO ₂ , a/A ratio, A-aDO ₂ and respiratory index Reduced MDA, IL-6, IL-8
Van et al. (2008) [43]	Randomised, controlled, single-blinded	Lower limb surgery	3 cycles of 5 min	20 (10, 10)	300 mmHg	Operated limb	NR	Venous blood pH, partial oxygen pressure (PO ₂), partial carbon dioxide pressure (PCO ₂), lactate, potassium, sodium, glucose Lipid peroxidation using venous blood thiobarbituric acid reactive substances (TBARS) level HR, SpO ₂ , MAP and spontaneous breathing rate (SRR)	No statistically significant findings between control and intervention
Hu et al. (2010) [44]	Randomised, controlled, triple-blinded	Cervical spondylosis decompression	3 cycles of 5 min	40 (20, 20)	200 mmHg	Right upper arm	Serum S-100B protein, serum neuron-specific enolase (NSE)	S-100B, NSE, median nerve somatosensory evoked potentials (SEPs), neurologic function recovery	Reduced serum S-100B and NSE, increased neurologic recovery rate

Table 4 (continued)

Authors	Type of study	Population	Intervention	Numbers (control, intervention)	Pressure	Location	Primary outcome	All reported outcome measures	Statistically significant results compared to placebo
Oh et al. (2020) [45]	Randomised, controlled, double-blinded	Shoulder surgery	3 cycles of 5 min	63 (34, 29)	Double systolic blood pressure	Opposite thigh to operated side	Regional cerebral oxygenation saturation (rScO ₂)	rScO ₂ , ratio of the arterial oxygen partial pressure to the fractional inspired oxygen (PF ratio) HR, MAP, Hct, lactate Serum IL-6, TNF-alpha, IL-10, TGF-beta	Higher rScO ₂
Park et al. (2018) [46]	Randomised, controlled, double-blinded	Orthopaedic surgery with history of IHD	3 cycles of 5 min	60 (30, 30)	250 mmHg or 50 mmHg above systolic blood pressure	Upper arm or calf that was not associated with the surgical field	Serum cardiac troponin I (cTnI) on day 1	Serum cTnI, creatine kinase (CK), creatine kinase myocardial band (CK-MB) ST-II segment of ECG lead II during surgery, and incidence of perioperative myocardial ischemic events Creatinine, incidence of acute kidney injury (AKI)	No statistically significant findings between control and intervention

IL-6 = interleukin 6; CRP = C reactive protein; TNF-alpha = tumour necrosis factor alpha; HR = heart rate per minute; MAP = mean arterial blood pressure; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; IL-10 = interleukine 10; PCR = polymerase chain reaction; Hb = haemoglobin; ESR = erythrocyte sedimentation rate; WCC = white cell count; IL-8 = interleukine 8; IL-2 = interleukine 2; IL-12 = interleukine 12; GM-CSF = granulocyte-macrophage colony stimulating factor; CoQ10 = coenzyme Q10; IFN-γ = interferon gamma; CPK = creatine phosphokinase; SpO2 = peripheral oxygen saturations; Hct = Haematocrit; NR = not reported. Other abbreviations already expanded in table

Two trials considered cerebral oxygenation [32, 45] and two measured peripheral oxygen levels [42, 43]. Regional cerebral oxygenation and venous and arterial measurements of partial pressure of oxygen (pO₂) were statistically significantly increased in all four of the RIC groups compared to control.

Five studies reported on post-operative pain scores and analgesia consumption [31, 35, 36, 38, 41], four of which reported significantly lower levels amongst RIC treated groups [31, 35, 38, 41]. In one of these studies, the length of stay was also shorter in the intervention group compared with control [31]. Muscle strength was measured in two studies [37, 41], one of which demonstrated preservation of quadriceps strength in the RIC group.

Clinical evidence in emergency orthopaedic surgery

Four manuscripts investigating RIC in individuals undergoing emergency orthopaedic surgery were identified. They all investigated hip fracture surgery in patients with cardiovascular risk factors, and their data were drawn from one RCT and its sub-studies. [48–50, 50]

The primary study recruited 648 patients with risk factors for cardiovascular disease across three centres. It was triple-blinded and included participants aged >45 years with one of the four cardiovascular risk factors in Table 5.

RIC was delivered after induction of anaesthesia prior to surgery by electric tourniquet device to the upper arm. Four cycles of five minutes occlusion at 200 mmHg were used. The treatment was found to be safe with no adverse events related to RIC reported.

The primary outcome in this study was myocardial injury (defined by troponin rise within the first 4 days of surgery), with a secondary end point of major adverse cardiovascular events (MACE) [47]. Of the 648 that were randomised, 573 were included in the intention-to-treat analysis (286 RIC: 287 control). Results showed that there were statistically significant reductions in myocardial injury among RIC treated individuals ($p = 0.002$), as well as reductions in non-ischaemic causes for troponin rise, suggesting non-cardiac benefits to RIC in hip fracture patients. In the secondary outcomes, only the incidence of perioperative myocardial infarction within 30 days was reduced ($p = 0.04$). At one year follow-up, there was no difference between intervention and control groups in rates of death or readmission and no extra protective effect on vascular events was observed in the RIC treated group from 30 days onwards [48].

In a single-centre sub-study of this RCT [49] 38 participants (18 RIC: 20 control) had reactive hyperaemia indices measured by digital pulse amplitude tonometry to assess endothelial function at day 1 post-operatively. Endothelial dysfunction criteria were met in 18% of the

RIC group and 40% of the control group indicating a beneficial effect from RIC, although this did not meet statistical significance. A further sub-study [50] evaluating the effects of RIC on thrombin generation, fibrinogen/fibrin turnover, plasminogen activation and fibrin structure pre-operatively and 2 h postoperatively, but did not find any differences between RIC and control groups.

Discussion

The use of RIC in pre-clinical studies appears to improve bone healing and reduce oxidative stress. In clinical studies overall, the impact of RIC on orthopaedic outcomes appears promising, in particular with reference to reducing pain scores, analgesic use and reducing cardiovascular risk. RIC is safe, with no adverse outcomes recorded related to RIC in the studies reviewed. In elective orthopaedic surgery, a variety of populations were studied including bone and ligament surgery. Outcome measures were varied but included measures related to hypothesised mechanisms of RIC effect.

Data from RCTs of pharmacological interventions, such as calcitonin, bisphosphonates, and monoclonal antibodies for fracture healing are mixed [51]; such therapies have not yet made it into routine clinical practice. Physical therapies such as low-intensity pulsed ultrasound can produce osteoinductive effects and accelerate fracture healing and tensile strength [52], however accessibility of the therapy limits applicability and data for benefit in deep fractures is limited [53]. RIC is simple low cost and easy to implement. The preclinical evidence in this review highlighted the beneficial effect of RIC on bone healing, potentially mediated by a reduction in oxidative stress and enhanced osteoblastic activity [29, 30, 30]. Formation of reactive oxygen species (ROS) in tissues in response to stress can impair the function of vital metalloenzymes in cells leading to inflammation, as well as the integrity of DNA and RNA itself, ultimately affecting cell function [54]. Organisms have thus evolved scavenging and repair systems in order to keep ROS in check. The mitigating effect that RIC has on ROS and oxidative stress has also been demonstrated in animal models of ischaemic stroke, possibly related to upregulation of nuclear factor-E2-related factor 2/heme oxygenase-1 pathway (Nrf2/HO-1) that plays a crucial role in upregulating expression of various antioxidant defence and anti-inflammatory genes [55]. The study by Sha et al. included in this review similarly revealed that a single dose of RIC led to upregulation of genes involved in ROS defence mechanisms in the muscle [34]. Identification of potentially relevant genes profiles and increasing sophistication and accessibility of genetic analysis techniques will hopefully mean that gene profiling as an outcome marker in RIC studies becomes increasingly common and reveals

a clearer understanding of which pathways are implicated in RIC protection. Further, effects on oxidative stress may be mediated by alterations to mitochondrial energy metabolism in response to RIC. Lv et al. (2020) showed in preclinical models of cerebral ischaemia that RIC preserved mitochondrial respiratory chain function in the brain and ameliorated apoptosis via endogenous mitochondrial pathways [56]. Not only does this represent another mechanism that alters oxidative stress response, but it may explain the attenuated adenosine triphosphate (ATP) depletion that occurs in RIC treated porcine skeletal muscle following experimental ischaemic stress [20].

Data on the effects of RIC on inflammatory mediator profiles were inconsistent from the studies included in this review. IL-6 was the most commonly evaluated in orthopaedic studies of RIC. It is a pleotropic cytokine secreted by T cells and macrophages to activate the immune response during infection or trauma [57] and is a marker of the proinflammatory response. Animal studies investigating the effect of RIC in experimental myocardial infarction [58, 59] have demonstrated that RIC, whether completed pre, per or post ischaemia, can lead to reductions in circulating IL-6. However, many clinical studies of ischaemic heart disease have not reproduced similar reductions [61, 62, 62]. Indeed, some clinical studies (renal transplant recipients) have reported increased levels of IL-6 in response to RIC [63], and so our understanding of the role IL-6 plays in inflammation may be oversimplified. The fact that IL-6 also acts as an osteoclast differentiation modulator, often involved in bone remodelling [64] may explain variations we observed in response to RIC in the in this review, as bone remodelling pathways are often activated in orthopaedic procedures. Further, variation in the type of surgery conducted, patient comorbid diseases and method of anaesthesia may also affect and confound inflammatory response and may have added to the variation in response seen in these studies.

Many orthopaedic procedures are conducted under general anaesthetic, associated with risk of impairments in pulmonary oxygenation, and cardiovascular and cerebrovascular events. RIC may mitigate such complications through its effects on vascular endothelial function and tissue perfusion. The endothelium of blood vessels plays a crucial role in vascular homeostasis by regulating vascular tone, releasing vasodilators and mediating platelet aggregation [65]. Impairments in endothelial function commonly occur following episodes of ischaemia and reperfusion, such as those occurring following myocardial infarction, stroke or even prolonged application of tourniquets [66]. RIC is thought to protect against such endothelial injury in humans via glucagon-like peptide-1 receptor-mediated pathways [67]. Such preservation of

endothelial function may be implicated in improved cerebral perfusion and oxygenation [68] as well as pulmonary gas exchange in ventilated patients [69] following RIC. Markers of cerebral oxygenation and peripheral partial pressures of oxygen were improved in RIC RCTs of total knee arthroplasty, lower limb surgery and shoulder surgery in this review. Cardioprotection following hip fracture surgery seen within the first 30 days [46] may be presumed to be related to endothelial preservation in part and is suggested from FMD sub-studies [49], but may also be related to preservation of mitochondrial function as previously demonstrated in clinical studies of RIC in coronary artery bypass surgery [70].

Of interest was the finding that RIC helped reduce pain scores and analgesia use following orthopaedic surgery. The relationship between RIC and pain is somewhat obscure. However, the central nervous system modulates nociceptive input from peripheral tissues, and the autonomic nervous system play a crucial role in this modulation [71]. It is known that RIC can influence the autonomic nervous system [72] and as such may also modulate the way nociceptive inputs are perceived. Although it is also possible that reduced levels of inflammation and tissue injury as a result of RIC may reduce pain and analgesia requirements. Studies are currently underway to evaluate the effect of RIC on pain in women with osteoarthritis [23].

This review has highlighted that a single dose of RIC delivered before orthopaedic procedures can result in a variety of beneficial effects on inflammation, organ function and pain as well as mitigate against common cardiovascular complications. RIC protocols used varied significantly in duration, frequency, pressure and limb conditioned. Further work on identifying the optimal dosing strategy of RIC delivery is still required in this cohort of patients. Indeed, whether repeated doses of RIC post procedure (RIPostC) may add further benefit is yet to be established. RIC may have immediate effects such as promoting endothelial release of vasodilating substances, and late effects such as upregulation of transcription factors that lead to expression of various proteins and enzymes involved in oxidative pathways and mitochondrial function [73]. Ekelof et al. in the PIXIE trial of hip fracture only identified an early protective effect of RIC on MACE which could be a result of the fact that they applied only a single dose at anaesthesia induction [46]. It may be that further doses of RIC conditioning post-operatively may have led to further cardioprotective effects at long term follow up and requires further investigation.

This review has a number of limitations. Firstly, there were 20 clinical manuscripts identified deriving data from 16 RCTs, only one of which included patients undergoing emergency surgery. Thus it is difficult to

Table 5 Characteristics of inclusion criteria in studies of RIC in people with cardiovascular risk factors undergoing emergency orthopaedic surgery

Inclusion criteria	Definition
Ischaemic heart disease	Angina pectoris, prior myocardial infarction, prior percutaneous coronary intervention or prior coronary artery bypass grafting
Peripheral arterial disease	Intermittent claudication, reduced peripheral arterial blood flow or previous vascular surgery due to peripheral arterial disease;
Previous Stroke	Prior history of ischaemic or haemorrhagic stroke
Cardiovascular risk factors	Age ≥ 70 years, congestive heart failure, previous transient ischaemic attack, diabetes and currently taking an oral hypoglycaemic agent or insulin, hypertension, preoperative serum creatinine concentration > 175 µmol/L, smoking within two years of surgery

generalise this data to emergency orthopaedic surgery cohorts. Second, there was significant heterogeneity in types of orthopaedic procedure undertaken (including duration of limb tourniquets applied) and the protocols of RIC used, which may account for some of the variation in outcomes seen. From the data included in this review, it is unclear if a greater pressure, ischaemic duration, or number of cycles results in a more profound physiological effect following RIC. These differing treatment parameters require further exploration. Furthermore, all included clinical studies investigated RIC delivered manually using a sphygmomanometer. Development of automated devices may offer ease of use for clinical staff, but would need to be balanced against cost. Additionally it is unclear whether surgical procedures operating under a tourniquet (further ischaemic stimulus) influences effects of RIC. However, 9 of the included clinical RCTs involved lower limb procedures operating under tourniquet conditions, many of whom reported physiological effects follow RIC compared to sham, suggesting additional benefit of ischaemia reperfusion cycles prior to surgery itself. Third, where general anaesthetics were used for procedures, types of anaesthetic agent were not always specified, and it is known that some anaesthetic agents can influence the effects of RIC. For example, pre-clinical models investigating the cardioprotective effects of RIC have shown that propofol negates the reduction in myocardial infarct size when compared to using sevoflurane or pentobarbital [74]. This may be due to the inhibitory effects of propofol on signal transducer pathways (e.g. signal transducer activator of transcription 5, stat5) or how it influences gaba-aminobutyric acid mediated vagal nerve activation [75]. Fourth, although participant characteristics were reported in many studies, very few included very elderly individuals (aged > 75 years for example) and those with multiple comorbidities, which makes generalisation to these cohorts also difficult, although our ageing population means these are the types of individuals we will see in clinical practice.

Future studies should ensure reporting of comorbid diseases such as diabetes, especially as conditions such as these, and potentially their treatments (e.g. sulphonylureas) may attenuate the effects of RIC [76]. Fifth, no studies included in this review used biomarkers to guide RIC therapy or monitor for treatment responses. While biomarkers of RIC have been proposed [77], they require further study before they can be used reliably to identify responders from non-responders, or guide the intensity of how RIC is delivered. Finally, bar the PIXIE trial, most of the included studies were small (n < 60) and as such, are prone to small study bias. Future studies should aim to be powered for clinically meaningful outcomes such as return to function and pain as primary outcomes. Long-term follow up is needed to assess functional recovery, bone healing and quality of life, as well as incorporating mechanistic evaluation as secondary measures, in order to understand whether RIC will eventually move from research intervention to clinical practice.

Conclusion and future directions

RIC is a safe, simple and economical therapy which has been shown to have promising effects in pre-clinical and clinical models of orthopaedic surgery. Pre-clinical work suggests enhancing effects on bone healing while clinical studies suggest positive effects on oxidative stress, inflammation, endothelial and vascular function, as well as clinical parameters such as cardiovascular complications, pain and analgesia use.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13018-025-05772-6>.

Additional file 1.

Additional file 2.

Acknowledgements

SB is supported by the Association of British Neurologists (Stroke Association/Berkeley Foundation). SB, AM and AA are supported by the National Institute

for Health and Care Research (NIHR) Sheffield Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care (DHSC).

Author contributions

AA conceptualised the manuscript. AA, AB, and TW performed the data collection. All authors were involved in interpretation of the data. AA and AB wrote the first draft of the manuscript. All authors were involved in critical revision of the manuscript. All authors read and approved the final manuscript.

Funding

SSB is supported by the Association of British Neurologists (Stroke Association/Berkeley Foundation). SSB, AM and AA are supported by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care (DHSC).

Availability of data and materials

The datasets generated during the current systematic review are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Protocol registration

This systematic review protocol was not registered or previously published.

Competing interests

None

Author details

¹MRes, Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield, UK. ²Department of Neuroscience, Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield, UK. ³Department of Neuroscience, Geriatrics and Stroke, Sheffield Institute of Translational Neuroscience, Royal Hallamshire Hospital, University of Sheffield, Glossop Rd, Sheffield S10 2JF, UK.

Received: 19 December 2024 Accepted: 31 March 2025

Published online: 07 May 2025

References

- Greenstein AS, Gorczyca JT. Orthopedic Surgery and the Geriatric Patient. *Clin Geriatr Med*. 2019 Feb;35(1):65–92. <https://doi.org/10.1016/j.cger.2018.08.007>.
- GBD 2019 Fracture Collaborators. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Healthy Longev*. 2021;2(9):e580–92. [https://doi.org/10.1016/S2666-7568\(21\)00172-0](https://doi.org/10.1016/S2666-7568(21)00172-0).
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789–1858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7) Erratum in: *Lancet*. 2019;393(10190):e44. [https://doi.org/10.1016/S0140-6736\(19\)31047-5](https://doi.org/10.1016/S0140-6736(19)31047-5).
- Blom AW, Donovan RL, Beswick AD, Whitehouse MR, Kunutsor SK. Common elective orthopaedic procedures and their clinical effectiveness: umbrella review of level 1 evidence. *BMJ*. 2021;7(374):n1511. <https://doi.org/10.1136/bmj.n1511>. PMID:34233885;PMCID:PMC8262448.
- Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. *Br J Anaesth*. 2017;119(2):249–57. <https://doi.org/10.1093/bja/aex137>. (PMID: 28854546).
- Heo SM, Harris I, Naylor J, Lewin AM. Complications to 6 months following total hip or knee arthroplasty: observations from an Australian clinical outcomes registry. *BMC Musculoskelet Disord*. 2020;21(1):602. <https://doi.org/10.1186/s12891-020-03612-8>. PMID:32912197;PMCID:PMC7488141.
- Leal J, Gray AM, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A. Impact of hip fracture on hospital care costs: a population-based study. *Osteoporos Int*. 2016;27(2):549–58. <https://doi.org/10.1007/s00198-015-3277-9>.
- Istianah U, Nurjannah I, Magetsari R. Post-discharge complications in postoperative patients with hip fracture. *J Clin Orthop Trauma*. 2020;24(14):8–13. <https://doi.org/10.1016/j.jcot.2020.10.045>. PMID:33717891;PMCID:PMC7919975.
- Physicians RCO. National Hip Fracture Database annual report 2019. 2019, London: RCP: rcplondon.ac.uk/projects/outputs/national-hip-fracture-database-nhfd-annual-report-2019.
- Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. *Am J Physiol*. 1998;275(5):H1542–7. <https://doi.org/10.1152/ajpheart.1998.275.5.H1542>. (PMID: 9815059).
- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74(5):1124–36. <https://doi.org/10.1161/01.cir.74.5.1124>. (PMID: 3769170).
- Baig S, Moyle B, Nair KPS, Redgrave J, Majid A, Ali A. Remote ischaemic conditioning for stroke: unanswered questions and future directions. *Stroke Vasc Neurol*. 2021;6(2):298–309. <https://doi.org/10.1136/svn-2020-000722>.
- Hougaard KD, Hjort N, Zeidler D, Sørensen L, Nørgaard A, Hansen TM, von Weitzel-Mudersbach P, Simonsen CZ, Damgaard D, Gotttrup H, Svendsen K, Rasmussen PV, Ribe LR, Mikkelsen IK, Nagenthiraja K, Cho TH, Redington AN, Bøtker HE, Østergaard L, Mouridsen K, Andersen G. Remote ischemic preconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. *Stroke*. 2014;45(1):159–67. <https://doi.org/10.1161/STROKEAHA.113.001346>. (Epub 2013 Nov 7 PMID: 24203849).
- Xu Y, Wang Y, Ji X. Immune and inflammatory mechanism of remote ischemic conditioning: A narrative review. *Brain Circ*. 2023;9(2):77–87. https://doi.org/10.4103/bc.bc_57_22. PMID:37576576;PMCID:PMC10419737.
- Zhang L, Diao Y, Chen G, Tanaka A, Eastwood GM, Bellomo R. Remote ischemic conditioning for kidney protection: A meta-analysis. *J Crit Care*. 2016;33:224–32. <https://doi.org/10.1016/j.jccr.2016.01.026>. (Epub 2016 Feb 10 PMID: 26936039).
- Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K. Naloxone blocks transferred preconditioning in isolated rabbit hearts. *J Mol Cell Cardiol*. 2001;33(9):1751–6. <https://doi.org/10.1006/jmcc.2001.1436>. (PMID: 11549353).
- Xiao L, Lu R, Hu CP, Deng HW, Li YJ. Delayed cardioprotection by intestinal preconditioning is mediated by calcitonin gene-related peptide. *Eur J Pharmacol*. 2001;427(2):131–5. [https://doi.org/10.1016/S0014-2999\(01\)01231-6](https://doi.org/10.1016/S0014-2999(01)01231-6). (PMID: 11557265).
- Brzozowski T, Konturek PC, Pajdo R, Kwieciński S, Sliwowski Z, Drozdowicz D, Ptak-Belowska A, Pawlik M, Konturek SJ, Pawlik WW, Hahn GG. Importance of brain-gut axis in the gastroprotection induced by gastric and remote preconditioning. *J Physiol Pharmacol*. 2004;55(1 Pt 2):165–77. (PMID: 15082876).
- Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, Cherepanov V, Downey GP, Liu PP, Cukerman E, Coles JG, Redington AN. The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. *Physiol Genomics*. 2004;19(1):143–50. <https://doi.org/10.1152/physiolgenomics.00046.2004>. (Epub 2004 Aug 10 PMID: 15304621).
- Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, Forrest CR, Pang CY. Noninvasive remote ischemic preconditioning for global

- protection of skeletal muscle against infarction. *Am J Physiol Heart Circ Physiol*. 2003;285(4):H1435–43. <https://doi.org/10.1152/ajpheart.00106.2003>. (Epub 2003 Jun 5 PMID: 12791590).
21. Corcoran D, Young R, Cialdella P, McCartney P, Bajrangee A, Hennigan B, Collison D, Carrick D, Shaukat A, Good R, Watkins S, McEntegart M, Watt J, Welsh P, Sattar N, McConnachie A, Oldroyd KG, Berry C. The effects of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. *Int J Cardiol*. 2018;1(252):24–30. <https://doi.org/10.1016/j.ijcard.2017.10.082>. PMID: 29249435; PMCID: PMC5761717.23.
 22. Khanna A, Gougoulas N, Maffulli N. Intermittent pneumatic compression in fracture and soft-tissue injuries healing. *Br Med Bull*. 2008;88(1):147–56. <https://doi.org/10.1093/bmb/ldn024>. (Epub 2008 Jul 1 PMID: 18596049).
 23. Biral TM, de Souza Cavina AP, Junior EP, Filho CATT, Vanderlei FM. Effects of remote ischemic conditioning on conditioned pain modulation and cardiac autonomic modulation in women with knee osteoarthritis: placebo-controlled randomized clinical trial protocol. *Trials*. 2023;24(1):502. <https://doi.org/10.1186/s13063-023-07527-2>. PMID: 37550703; PMCID: PMC10405415.
 24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. <https://doi.org/10.1371/journal.pmed.1000097>.
 25. Hooijmans CR, Ritskes-Boitinga M. Progress in using systematic reviews of animal studies to improve translational research. *PLoS Med*. 2013;10(7):e1001482. <https://doi.org/10.1371/journal.pmed.1001482>.
 26. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Phys Ther*. 2003;83(8):713–21. (PMID: 12882612).
 27. Ryan R. Cochrane Consumers and Communication Review Group. 'Cochrane Consumers and Communication Review Group: data synthesis and analysis'. <http://cccr.cochrane.org>, 2013.
 28. Çatma MF, et al. Remote ischemic preconditioning enhances fracture healing. *J Orthop*. 2015;12(4):168–73.
 29. Zhou M, et al. Effects of remote ischemic post-conditioning on fracture healing in rats. *Mol Med Rep*. 2017;15(5):3186–92.
 30. Qiao J, et al. Comparison of remote ischemic preconditioning and intermittent hypoxia training in fracture healing. *Mol Med Rep*. 2019;19(3):1867–74.
 31. Memtsoudis SG, et al. Perioperative inflammatory response in total knee arthroplasty patients: impact of limb preconditioning. *Reg Anesth Pain Med*. 2010;35(5):412–6.
 32. Oh CS, et al. Impact of remote ischaemic preconditioning on cerebral oxygenation during total knee arthroplasty. *Int J Med Sci*. 2017;14(2):115–22.
 33. Murphy T, et al. Transcriptional responses in the adaptation to ischaemia-reperfusion injury: a study of the effect of ischaemic preconditioning in total knee arthroplasty patients. *J Transl Med*. 2010;8:46.
 34. Sha Y, et al. Protective effect of ischaemic preconditioning in total knee arthroplasty. *Eur Rev Med Pharmacol Sci*. 2014;18(10):1559–66.
 35. Memtsoudis SG, et al. Does limb preconditioning reduce pain after total knee arthroplasty? A randomized, double-blind study. *Clin Orthop Relat Res*. 2014;472(5):1467–74.
 36. Leucharasmee P, et al. Coenzyme Q10 and ischemic preconditioning potentially prevent tourniquet-induced ischemia/reperfusion in knee arthroplasty, but combined pretreatment possibly neutralizes their beneficial effects. *Antioxidants*. 2022;11(2):419. <https://doi.org/10.3390/antiox11020419>.
 37. Leucharasmee P, et al. Ischemic preconditioning upregulates Mitofusin2 and preserves muscle strength in tourniquet-induced ischemia/reperfusion. *J Orthop Translat*. 2022;35:113–21.
 38. Arian MN, et al. Effect of Remote Ischemic Preconditioning in Total Knee Arthroplasty on Thiol-Disulfide Balance: a Randomized Controlled Study. *Acta Chir Orthop Traumatol Cech*. 2023;90(5):314–22.
 39. Sullivan PJ, et al. Cyclical ischaemic preconditioning modulates the adaptive immune response in human limb ischaemia-reperfusion injury. *Br J Surg*. 2009;96(4):381–90.
 40. Koca K, et al. The role of preconditioning and N-acetylcysteine on oxidative stress resulting from tourniquet-induced ischemia-reperfusion in arthroscopic knee surgery. *J Trauma*. 2011;70(3):717–23.
 41. Orban JC, et al. Effects of acetylcysteine and ischaemic preconditioning on muscular function and postoperative pain after orthopaedic surgery using a pneumatic tourniquet. *Eur J Anaesthesiol*. 2006;23(12):1025–30.
 42. Lin LN, et al. Ischemic preconditioning attenuates pulmonary dysfunction after unilateral thigh tourniquet-induced ischemia-reperfusion. *Anesth Analg*. 2010;111(2):539–43.
 43. Van M, et al. Ischaemic preconditioning attenuates haemodynamic response and lipid peroxidation in lower-extremity surgery with unilateral pneumatic tourniquet application: a clinical pilot study. *Adv Ther*. 2008;25(4):355–66.
 44. Hu S, et al. Effects of remote ischemic preconditioning on biochemical markers and neurologic outcomes in patients undergoing elective cervical decompression surgery: a prospective randomized controlled trial. *J Neurosurg Anesthesiol*. 2010;22(1):46–52.
 45. Oh CS, et al. Effects of remote ischemic preconditioning on regional cerebral oxygen saturation in patients in the beach chair position during shoulder surgery: A double-blind randomized controlled trial. *J Clin Anesth*. 2020;61: 109661.
 46. Park SK, et al. Effect of remote ischaemic preconditioning in patients with ischaemic heart disease undergoing orthopaedic surgery: a randomized controlled trial. *Br J Anaesth*. 2018;120(1):198–200.
 47. Ekeloef S, et al. The effect of remote ischaemic preconditioning on myocardial injury in emergency hip fracture surgery (PIXIE trial): phase II randomised clinical trial. *BMJ*. 2019;367: l6395.
 48. Ekeloef S, et al. Cardiovascular events in patients undergoing hip fracture surgery treated with remote ischaemic preconditioning: 1-year follow-up of a randomised clinical trial. *Anaesthesia*. 2021;76(8):1042–50.
 49. Ekeloef S, et al. The effect of remote ischaemic preconditioning on endothelial function after hip fracture surgery. *Acta Anaesthesiol Scand*. 2021;65(2):169–75.
 50. Wahlström KL, et al. Effect of remote ischemic preconditioning on fibrin formation and metabolism in patients undergoing hip fracture surgery: a randomized clinical trial. *Blood Coagul Fibrinolysis*. 2021;33:25–33.
 51. Migliorini F, Cocconi F, Vecchio G, Schaefer L, Koettnitz J, Maffulli N. Pharmacological agents for bone fracture healing: talking points from recent clinical trials. *Exp Opin Investig Drugs*. 2023;32(9):855–65. <https://doi.org/10.1080/13543784.2023.2263352>.
 52. Martínez de Albornoz P, Khanna A, Longo UG, Forriol F, Maffulli N. The evidence of low-intensity pulsed ultrasound for in vitro, animal and human fracture healing. *Br Med Bull*. 2011;100(1):39–57. <https://doi.org/10.1093/bmb/ldr006>.
 53. Palanisamy P, Alam M, Li S, Chow SKH, Zheng, YP. Low-intensity pulsed ultrasound stimulation for bone fractures healing: a review. *J Ultrasound Med*. 2022;41(3):547–63. <https://doi.org/10.1002/jum.15738>.
 54. Imlay J. The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium. *Nat Rev Microbiol*. 2013;11:443–54. <https://doi.org/10.1038/nrmicro3032>.
 55. Sun Y-Y, Zhu H-J, Zhao R-Y, Zhou S-Y, Wang M-Q, Yang Y, Guo Z-N. Remote ischemic conditioning attenuates oxidative stress and inflammation via the Nrf2/HO-1 pathway in MCAO mice. *Redox Biol*. 2023;66:102852. <https://doi.org/10.1016/j.redox.2023.102852>.
 56. Lv J, Guan W, You Q, Deng L, Zhu Y, Guo K, Gao X, Kong J, Yang C. RIPC provides neuroprotection against ischemic stroke by suppressing apoptosis via the mitochondrial pathway. *Sci Rep*. 2020;10(1):5361. <https://doi.org/10.1038/s41598-020-62336-w>. PMID: 32210331; PMCID: PMC7093414.
 57. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014;6(10): a016295. <https://doi.org/10.1101/cshperspect.a016295>. PMID: 25190079; PMCID: PMC4176007.
 58. Wang Q, Liu GP, Xue FS, Wang SY, Cui XL, Li RP, Yang GZ, Sun C, Liao X. Combined vagal stimulation and limb remote ischemic preconditioning enhances cardioprotection via an anti-inflammatory pathway. *Inflammation*. 2015;38(5):1748–60. <https://doi.org/10.1007/s10753-015-0152-y>. (PMID: 25772113).
 59. Zhang J, Zhang J, Yu P, Chen M, Peng Q, Wang Z, Dong N. Remote ischaemic preconditioning and sevoflurane postconditioning synergistically protect rats from myocardial injury induced by ischemia and reperfusion partly via inhibition TLR4/MyD88/NF-κB Signaling pathway. *Cell Physiol Biochem*. 2017;41(1):22–32. <https://doi.org/10.1159/000455815>. (Epub 2017 Jan 16 PMID: 28135708).
 60. Ney J, Hoffmann K, Meybohm P, Goetzenich A, Kraemer S, Benstöm C, Weber NC, Bickenbach J, Rossaint R, Marx G, Zacharowski K, Bernhagen J,

- Stoppe C. Remote ischemic preconditioning does not affect the release of humoral factors in propofol-anesthetized cardiac surgery patients: a secondary analysis of the RIPHeart study. *Int J Mol Sci*. 2018;19(4):1094. <https://doi.org/10.3390/ijms19041094>. PMID:29621201;PMCID:PMC5979505.
61. Nederlof R, Weber NC, Juffermans NP, de Mol BA, Hollmann MW, Preckel B, Zuurbier CJ. A randomized trial of remote ischemic preconditioning and control treatment for cardioprotection in sevoflurane-anesthetized CABG patients. *BMC Anesthesiol*. 2017;17(1):51. <https://doi.org/10.1186/s12871-017-0330-6>. PMID:28356068;PMCID:PMC5372281.
 62. Gedik N, Kottenberg E, Thielmann M, Frey UH, Jakob H, Peters J, Heusch G, Kleinbongard P. Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization. *Sci Rep*. 2017;7(1):12660. <https://doi.org/10.1038/s41598-017-12833-2>. PMID:28978919;PMCID:PMC5627278.
 63. Zapata-Chavira H, Hernández-Guedea M, Jiménez-Pérez JC, Pérez-Rodríguez E, Muñoz-Espinosa L, Muñoz-Maldonado G, Cordero-Pérez P. Modulation of remote ischemic preconditioning by proinflammatory cytokines in renal transplant recipients. *J Invest Surg*. 2019;32(1):63–71. <https://doi.org/10.1080/08941939.2017.1375052>. (Epub 2017 Oct 30 PMID: 29083941).
 64. Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. *Front Endocrinol (Lausanne)*. 2019;8(9):788. <https://doi.org/10.3389/fendo.2018.00788>. PMID:30671025;PMCID:PMC6333051.
 65. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115–26.
 66. Botts SR, Fish JE, Howe KL. Dysfunctional vascular endothelium as a driver of atherosclerosis: emerging insights into pathogenesis and treatment. *Front Pharmacol*. 2021;22(12): 787541. <https://doi.org/10.3389/fphar.2021.787541>. PMID:35002720;PMCID:PMC8727904.
 67. Verouhis D, Saleh N, Settergren M, Sörensson P, Gourine A, Pernow J. Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans. *Int J Cardiol*. 2019;1(274):40–4. <https://doi.org/10.1016/j.ijcard.2018.09.061>. (Epub 2018 Sep 22 PMID: 30268384).
 68. Xu J, Zhang Q, Rajah GB, Zhao W, Wu F, Ding Y, Zhang B, Guo W, Yang Q, Xing X, Li S, Ji X. Daily remote ischemic conditioning can improve cerebral perfusion and slow arterial progression of adult moyamoya disease—a randomized controlled study. *Front Neurol*. 2022;3(12): 811854. <https://doi.org/10.3389/fneur.2021.811854>. PMID:35185755;PMCID:PMC8850829.
 69. Kashiwagi S, Mihara T, Yokoi A, Yokoyama C, Nakajima D, Goto T. Effect of remote ischemic preconditioning on lung function after surgery under general anesthesia: a systematic review and meta-analysis. *Sci Rep*. 2023;13(1):17720. <https://doi.org/10.1038/s41598-023-44833-w>. PMID: 37853024;PMCID:PMC10584824.
 70. Slagsvold KH, Rognmo O, Høydal M, Wisløff U, Wahba A. Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. *Circ Res*. 2014;114(5):851–9. <https://doi.org/10.1161/CIRCRESAHA.114.302751>. (Epub 2013 Dec 26 PMID: 24371264).
 71. Randich A, Maixner W. Interactions between cardiovascular and pain regulatory systems. *Neurosci Biobehav Rev* Fall. 1984;8(3):343–67. [https://doi.org/10.1016/0149-7634\(84\)90057-5](https://doi.org/10.1016/0149-7634(84)90057-5).
 72. Wei L, Liang H, Mo M, Liu Z, Ye R, Ye H, Ouyang W, Yu W, Zhao W, Zhang X. The effect of remote ischemic postconditioning on autonomic function in patients with acute ischemic stroke: A Randomized Controlled Trial. *Complement Ther Med*. 2020;54: 102541. <https://doi.org/10.1016/j.ctim.2020.102541>. (Epub 2020 Aug 18 PMID: 33183660).
 73. Behnenburg F, van Caster P, Bunte S, Brandenburger T, Heinen A, Hollmann MW, Huhn R. Impact of anesthetic regimen on remote ischemic preconditioning in the rat heart in vivo. *Anesth Analg*. 2018;126(4):1377–80. <https://doi.org/10.1213/ANE.0000000000002563>. (PMID: 29077609).
 74. Chen G, Thakkar M, Robinson C, Doré S. Limb remote ischemic conditioning: mechanisms, anesthetics, and the potential for expanding therapeutic options. *Front Neurol*. 2018;6(9):40. <https://doi.org/10.3389/fneur.2018.00040>. PMID:29467715;PMCID:PMC5808199.
 75. Heusch G. Remote ischemic conditioning in cardiovascular surgery. *J Cardiovasc Pharmacol Ther*. 2017;22:297–301.
 76. Kottenberg E, Thielmann M, Kleinbongard P, Frey UH, Heine T, Jakob H, Heusch G, Peters J. Myocardial protection by remote ischaemic preconditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. *Acta Anaesthesiol Scand*. 2014;58(4):453–62. <https://doi.org/10.1111/aas.12278>. (Epub 2014 Feb 18 PMID: 24548338).
 77. Appleton JP, O'Sullivan SE, Hedstrom A, May JA, Donnelly R, Sprigg N, Bath PM, England TJ. Blood markers in remote ischaemic conditioning for acute ischaemic stroke: data from the REMote ischaemic Conditioning After Stroke Trial. *Eur J Neurol*. 2021;28(4):1225–33. <https://doi.org/10.1111/ene.14650>. (Epub 2020 Dec 14 PMID: 33217147).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.